# Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

> **NCT05835895** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Genascence Corporation** · enrollment: 67 (actual)

## Conditions studied

- Osteoarthritis, Knee
- Osteo Arthritis Knee
- Knee Osteoarthritis

## Interventions

- **GENETIC:** GNSC-001
- **DRUG:** transient immune-modulation
- **DRUG:** transient immune-modulation
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05835895
- **Lead sponsor:** Genascence Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-12
- **Primary completion:** 2025-04-08
- **Final completion:** 2029-05
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05835895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05835895, "Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05835895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*